Scientists at national health institutes have identified an antibody from an HIV-infected person who potently neutralized 98 percent of the strains isolated from HIV already tested, including 16 from 20 strains resistant to other antibodies of the same class. The remarkable amplitude and potency of this antibody, called N6, makes it an attractive candidate for the development of a drug / vaccine potentially capable of treating or preventing HIV infection, the researchers say.
Scientists, led by Mark Connors, MD, of NIH of the National Institute of Allergy and Infectious Diseases (NIAID), also monitored the evolution of N6 over time to understand how the ability to neutralize almost all strains of HIV has developed. This information will help idealize the design of vaccines to cause the appearance of highly neutralizing antibodies.
Identification of neutralizing antibodies against HIV in general has been difficult because the virus rapidly changes its surface proteins as a form of evasion in one already described here "arms race recognition by the immune system. "
In 2010, scientists at the Vaccine Research Center (NIAID VRC) discovered an antibody called VRC01 capable of preventing up to ninety percent of the virus strains of the Human Immunodeficiency Virus from infecting human cells. Like VRC01, N6 blocks infection by binding to a part of the HIV envelope called binding site CD4, preventing the virus from attaching itself to immune cells.
Findings from the present study showed that N6 evolved from a unique binding mode that depends less on an area variable of the HIV viral envelope, known as the V5 region, and focuses more on regions which have changed relatively little among HIV strains. This allows N6 to tolerate changes in the HIV envelope, including in the glucose attachment in the V5 regions, an important mechanism by which HIV resistance to other VRC01 class antibodies develops.
The new findings suggest that the N6 may represent advantages over VRC01, which is currently being evaluated through venous infusion in clinical trials to see if it can safely prevent HIV infection in humans. Because of its potency, the N6 antibody may offer a stronger and more durable reaction in prevention and treatment and another of the benefits is that researchers may be able to administer subcutaneously (in fat under the skin) rather than via (it would be more or less the same as I do with four injections of Clexane ®). In addition, its ability to neutralize almost all strains of HIV would be advantageous for both prevention and treatment strategies.
Translated by Claudio Souza the original NIH Scientists Identify Potent Antibody Neutralizes que Nearly All HIV Strains
reviewed by Bob Volpe - Tantum Nominum Nulum pair Elogium
J Huang, BH Kang, and Ishida, T Zhou et al. Identification of the CD4-binding site antibody to HIV que evolvednear-pan neutralizationbreadth. Immunity DOI: 10.1016 / j.immuni.2016.10.027 (2016).
NIAID Director Anthony S. Fauci, MD, isavailable to comment on the research. Mark Connors, MD, chief of the HIV-SpecificImmunitySection in NIAID'sLaboratory of Immunoregulation and the seniorauthor of the paper, alsoisavailable.
The researchteamincludedscientists from NIAID'sLaboratory of Immunoregulation and Vaccine Research Center.
Content last reviewed on November 15, 2016